Multidrug-resistant tuberculosis and migration to Europe

Clinical Microbiology and Infection

Volumn 23, Issue 3, 2017, Pages 141-146

  Hargreaves, S ^a   Lonnroth K ^b,c   Nellums, L B ^a   Olaru, I D ^d,e   Nathavitharana, R R ^a,f   Norredam, M ^g,h   Friedland, J S ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b KAROLINSKA INSTITUTE   (Sweden)

^c WORLD HEALTH ORGANIZATION   (Switzerland)

^d RESEARCH CENTER BORSTEL   (Germany)

^e Clinical Tuberculosis Center   (Germany)

^f BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^g UNIVERSITY OF COPENHAGEN   (Denmark)

^h HVIDOVRE HOSPITAL   (Denmark)

Author keywords

Delivery; Drug resistance; Europe; Health service delivery; Latent tuberculosis; migration; Multidrug resistant tuberculosis; Screening; Tuberculosis

Indexed keywords

BIBLIOGRAPHIC DATABASE; EMBASE; EUROPE; GOOGLE SCHOLAR; HEALTH; HIGH RISK POPULATION; HUMAN; INCIDENCE; INFECTION PREVENTION; INFECTION RISK; MASS SCREENING; MEDLINE; MIGRANT; MIGRATION; MULTIDRUG RESISTANT TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; PUBLIC HEALTH SERVICE; PUBLIC POLICY; RESOURCE MANAGEMENT; REVIEW; SYSTEMATIC REVIEW; TREATMENT OUTCOME; DIAGNOSTIC TEST; DISEASE TRANSMISSION; INFECTION CONTROL; MEDICATION COMPLIANCE; PREVENTION AND CONTROL; TRANSMISSION; TUBERCULOSIS, MULTIDRUG-RESISTANT;

TUBERCULOSTATIC AGENT;

ANTITUBERCULAR AGENTS; DIAGNOSTIC TESTS, ROUTINE; DISEASE TRANSMISSION, INFECTIOUS; EMIGRATION AND IMMIGRATION; EUROPE; HUMANS; INFECTION CONTROL; MEDICATION ADHERENCE; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 85006161397     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1016/j.cmi.2016.09.009     Document Type: Review

References (61)

1. [1] Tackling drug-resistant infections globally: final report and recommendations. O'Neill, J., (eds.) The review on antimicrobial resistance, 2016, UK Department of Health, HM Treasury, Foreign and Commonwealth Office, Wellcome Trust, London.
2. [2] Hargreaves, S., Nellums, L., Friedland, J., Goldberg, J., Murwill, P., Jones, L., Extending migrant charging into emergency services. Br Med J, 352, 2016.
3. [3] van der Werf, M., Zellweger, J., Stefanelli, P., Miglietta, A., Pezzotti, P., Fazio, C., et al. Impact of migration on tuberculosis epidemiology and control in the EU/EEA. Euro Surveill, 21, 2016.
4. [4] Broekmans, J., Migliori, G., Rieder, H., Lees, J., Ruutu, P., Loddenkemper, R., et al. European framework for tuberculosis control and elimination in countries with a low incidence. Eur Respir J 19 (2002), 765–775.
5. [5] European Centre for Disease Prevention and Control/WHO Regional Office for Europe, Tuberculosis surveillance and monitoring in Europe 2014. 2014, European Centre for Disease Prevention and Control, Stockholm.
6. [6] Migliori, G.B., Richardson, M.D.A., Sotgiu, G., Lange, C., Multidrug-resistant and extensively drug-resistant tuberculosis in the West. Europe and United States: epidemiology, surveillance, and control. Clin Chest Med 30 (2009), 637–665.
7. [7] ECDC, Assessing the burden of key infectious diseases affecting migrant populations in the EU/EEA. 2014, European Centre for Disease Prevention and Control, Solna, Sweden.
8. [8] Bernard, C., Brossier, F., Sougakoff, W., Veziris, N., Frechet-Jachym, M., Metivier, N., et al. A surge of MDR and XDR tuberculosis in France among patients born in the former Soviet Union. Euro Surveill, 18, 2013, 20555.
9. [9] Ruesen, C., van Gageldonk-Lafeber, A.B., de Vries, G., Erkens, C.G., van Rest, J., Korthals Altes, H., et al. Extent and origin of resistance to antituberculosis drugs in The Netherlands, 1993 to 2011. Euro Surveill, 19, 2014.
10. [10] Inigo, J., Garcia De Viedma, D., Arce, A., Palenque, E., Alonso Rodriguez, N., Rodriguez, E., et al. Analysis of changes in recent tuberculosis transmission patterns after a sharp increase in immigration. J Clin Microbiol 45 (2007), 63–69.
11. [11] Zignol, M., Dara, M., Dean, A.S., Falzon, D., Dadu, A., Kremer, K., et al. Drug-resistant tuberculosis in the WHO European region: an analysis of surveillance data. Drug Resist Updat 16 (2013), 108–115.
12. [12] Falzon, D., Infuso, A., Ait-Belghiti, F., In the European Union, TB patients from former Soviet countries have a high risk of multidrug resistance. Int J Tuberc Lung Dis 10 (2006), 954–958.
13. [13] Eurostat, Migration and migrant population statistics. Eurostat, 2015.
14. [14] IOM, EU migrant, refugee arrivals by land and sea approach one million in 2015. 2015, International Organization for Migration, London.
15. [15] WHO, Global tuberculosis report 2015., 2015, World Health Organization, Geneva.
16. [16] Seung, K.J., Keshavjee, S., Rich, M.L., Multidrug-resistant tuberculosis and extensively drug-resistant tuberculosis. Cold Spring Harb Perspect Med, 5, 2015, a017863.
17. [17] Walls, T., Shingadia, D., The epidemiology of tuberculosis in Europe. Arch Dis Child 92 (2007), 726–729.
18. [18] European Centre for Disease Prevention and Control, Molecular typing for surveillance of multidrug-resistant tuberculosis in the EU/EEA—January 2016. 2016, ECDC, Stockholm.
19. [19] Ködmön, C., Zucs, P., van der Werf, M., Migration-related tuberculosis: epidemiology and characteristics of tuberculosis cases originating outside the European Union and European Economic Area, 2007 to 2013. Euro Surveill, 21, 2016, 12.
20. [20] Hollo, V., Kotila, S., Ködmön, C., Zucs, P., van der Werf, M., The effect of migration within the European Union/European Economic Area on the distribution of tuberculosis, 2007 to 2013. Euro Surveill, 21, 2016, 12.
21. [21] Ricks, P.M., Cain, K.P., Oeltmann, J.E., Kammerer, J.S., Moonan, P.K., Estimating the burden of tuberculosis among foreign-born persons acquired prior to entering the US, 2005–2009. PLoS One, 6, 2011, e27405.
22. [22] Esmail, H., Barry, C., Young, D., Wilkinson, R., The ongoing challenge of latent tuberculosis. Phil Trans R Soc B, 369, 2014, 20130437.
23. [23] Hemming, S., Windish, P., Hall, J., Story, A., Lipman, M., Treating TB patients with no entitlement to social support-welcome to the social jungle. Thorax, 65, 2010, A146.
24. [24] Lillebaek, T., Andersen, A.B., Dirksen, A., Smith, E., Skovgaard, L.T., Kok-Jensen, A., Persistent high incidence of tuberculosis in immigrants in a low-incidence country. Emerg Infect Dis 8 (2002), 679–684.
25. [25] Ormerod, L.P., Green, R.M., Gray, S., Are there still effects on indian subcontinent ethnic tuberculosis of return visits?: a longitudinal study 1978–97. J Infect 43 (2001), 132–134.
26. [26] Lönnroth, K., Migliori, G.B., Abubakar, I., D'Ambrosio, L., De Vries, G., Diel, R., et al. Towards tuberculosis elimination: an action framework for low-incidence countries. Eur Respir J 45 (2015), 928–952.
27. [27] Lillebaek, T., Andersen, Å.B., Bauer, J., Dirksen, A., Glismann, S., de Haas, P., et al. Risk of Mycobacterium tuberculosis transmission in a low-incidence country due to immigration from high-incidence areas. J Clin Microbiol 39 (2001), 855–861.
28. [28] Cookson, S.T., Abaza, H., Clarke, K.R., Burton, A., Sabrah, N.A., Rumman, K.A., et al. Impact of and response to increased tuberculosis prevalence among Syrian refugees compared with Jordanian tuberculosis prevalence: case study of a tuberculosis public health strategy. Conflict and Health, 9, 2015, 1.
29. [29] Dudnyk, A., Rzhepishevska, O., Rogach, K., Kutsyna, G., Lange, C., Multidrug-resistant tuberculosis in Ukraine at a time of military conflict. Int J Tuberc Lung Dis 19 (2015), 492–493.
30. [30] MdM, Medecins du monde european observatory on access to healthcare: Access to health care for undocumented migrants in 11 European countries. 2009, Medecins du Monde, Paris.
31. [31] Warne, B., Weld, L.H., Cramer, J.P., Field, V.K., Grobusch, M.P., Caumes, E., et al. Travel-related infection in European travelers, eurotravnet 2011. J Travel Med 21 (2014), 248–254.
32. [32] Lunt, N., Smith, R., Exworthy, M., Green, S.T., Horsfall, D., Mannion, R., Medical tourism: treatments, markets and health system implications: a scoping review. 2011, OECD, Paris 55 p. Available at: http://www.Oecd.Org/dataoecd/51/11/48723982.Pdf.
33. [33] Lange, C., Periodic migration driving the TB epidemic in Europe. 2016, ECCMID, Amsterdam, The Netherlands.
34. [34] Denkinger, C.M., Schumacher, S.G., Boehme, C.C., Dendukuri, N., Pai, M., Steingart, K.R., Xpert MTB/RIF assay for the diagnosis of extrapulmonary tuberculosis: a systematic review and meta-analysis. Eur Respir J, 2014 erj00078–02014.
35. [35] Morgan, M., Kalantri, S., Flores, L., Pai, M., A commercial line probe assay for the rapid detection of rifampicin resistance in Mycobacterium tuberculosis: a systematic review and meta-analysis. BMC Infect Dis, 5, 2005, 1.
36. [36] WHO, Global tuberculosis report 2014., 2014, World Health Organization, Geneva.
37. [37] WHO, Tuberculosis diagnostics: molecular line-probe assay for the detection of resistance to second-line anti-TB drugs (SL-LPA). 2016, World Health Organization, Geneva.
38. [38] Pareek, M., Baussano, I., Abubakar, I., Dye, C., Lalvani, A., Evaluation of immigrant tuberculosis screening in industrialized countries. Emerg Infect Dis 18 (2012), 1422–1429.
39. [39] Dara, M., Solovic, I., Sotgiu, G., D'Ambrosio, L., Centis, R., Tran, R., et al. Tuberculosis care among refugees arriving in Europe: A ERS/WHO Europe region survey of current practices. Eur Respir J, 2016 ERJ-00840–02016.
40. [40] Klinkenberg, E., Manissero, D., Semenza, J., Verver, S., Migrant tuberculosis screening in the EU/EEA: yield, coverage and limitations. Eur Respir J 34 (2009), 1180–1189.
41. [41] Alvarez, G.G., Gushulak, B., Rumman, K.A., Altpeter, E., Chemtob, D., Douglas, P., et al. A comparative examination of tuberculosis immigration medical screening programs from selected countries with high immigration and low tuberculosis incidence rates. BMC Infect Dis, 11, 2011, 1.
42. [42] Aldridge, R.W., Yates, T.A., Zenner, D., White, P.J., Abubakar, I., Hayward, A.C., Pre-entry screening programmes for tuberculosis in migrants to low-incidence countries: a systematic review and meta-analysis. Lancet Infect Dis 14 (2014), 1240–1249.
43. [43] Kamper-Jørgensen, Z., Andersen, A.B., Kok-Jensen, A., Kamper-Jørgensen, M., Bygbjerg, I.C., Andersen, P.H., et al. Migrant tuberculosis: the extent of transmission in a low burden country. BMC Infect Dis, 12, 2012, 1.
44. [44] Godoy, P., Caylà, J.A., Carmona, G., Camps, N., Álvarez, J., Rodés, A., et al. Immigrants do not transmit tuberculosis more than indigenous patients in Catalonia (Spain). Tuberculosis 93 (2013), 456–460.
45. [45] Gulland, A., Refugees pose little health risk, says WHO. BMJ, 351, 2015, h4808.
46. [46] Sandgren, A., Schepisi, M.S., Sotgiu, G., Huitric, E., Migliori, G.B., Manissero, D., et al. Tuberculosis transmission between foreign- and native-born populations in the EU/EEA: a systematic review. Eur Respir J 43 (2014), 1159–1171.
47. [47] Fraser, A., Paul, M., Attamna, A., Leibovici, L., Treatment of latent tuberculosis in persons at risk for multidrug-resistant tuberculosis: systematic review. Int J Tuberc Lung Dis 10 (2006), 19–23.
48. [48] European Centre for Disease Prevention and Control, Management of contacts of MDR TB and XDR TB patients. 2012, ECDC, Stockholm.
49. [49] Getahun, H., Matteelli, A., Abubakar, I., Aziz, M.A., Baddeley, A., Barreira, D., et al. Management of latent Mycobacterium tuberculosis infection: WHO guidelines for low tuberculosis burden countries. Eur Respir J, 2015 ERJ-01245–02015.
50. [50] Anderson, L., Tamne, S., Watson, J., Cohen, T., Mitnick, C., Brown, T., et al. Treatment outcome of multi-drug resistant tuberculosis in the United Kingdom: retrospective-prospective cohort study from 2004 to 2007. Euro Surveill 18 (2013), 1028–1035.
51. [51] Centis, R., Ianni, A., Migliori, G.B., Evaluation of tuberculosis treatment results in Italy, report 1998. Tuberculosis section of the national AIPO study group on infectious disease and the SMIRA group. Monaldi Arch Chest Dis 55 (2000), 293–298.
52. [52] Faustini, A., Hall, A., Perucci, C., Tuberculosis treatment outcomes in Europe: a systematic review. Eur Respir J 26 (2005), 503–510.
53. [53] WHO, WHO treatment guidelines for drug-resistant tuberculosis: 2016 update. 2016, World Health Organization, Geneva.
54. [54] WHO, Tuberculosis: Fact sheet no. 104. 2015, World Health Organization, Geneva.
55. [55] Laurence, Y.V., Griffiths, U.K., Vassall, A., Costs to health services and the patient of treating tuberculosis: a systematic literature review. Pharmacoeconomics 33 (2015), 939–955.
56. [56] Schwartzman, K., Oxlade, O., Barr, R.G., Grimard, F., Acosta, I., Baez, J., et al. Domestic returns from investment in the control of tuberculosis in other countries. N Engl J Med 353 (2005), 1008–1020.
57. [57] Fitzpatrick, C., Floyd, K., A systematic review of the cost and cost effectiveness of treatment for multidrug-resistant tuberculosis. Pharmacoeconomics 30 (2012), 63–80.
58. [58] Abarca Tomas, B., Pell, C., Bueno Cavanillas, A., Guillen Solvas, J., Pool, R., Roura, M., Tuberculosis in migrant populations. A systematic review of the qualitative literature. PLoS One, 8, 2013, e82440.
59. [59] Story, A., Garfein, R.S., Hayward, A., Rusovich, V., Dadu, A., Soltan, V., et al. Monitoring therapy adherence of tuberculosis patients by using video-enabled electronic devices. Emerg Infect Dis, 22, 2016, 538.
60. [60] Kodjo, C., Cultural competence in clinician communication. Pediatr Rev/Am Acad Pediatr, 30, 2009, 57.
61. [61] Aubry, A., Bernard, C., Jarlier, V., Robert, J., Veziris, N., Cases of multidrug resistant (MDR) and extensively drug-resistant (XDR) tuberculosis, 2006–2015. 2016, National Reference Center for Mycobacteria and Mycobacterial Resistance to Anti-Tuberculosis Drugs (CNR-MYRMA), Paris.